PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
PharmAla Biotech has expressed disappointment following the USFDA’s request for an additional Phase 3 trial for MDMA-assisted therapy for PTSD, which they supply for clinical trials. Despite this setback, the company remains optimistic due to its patent issuance for ALA-002, a novel MDMA derivative aimed at addressing safety concerns. PharmAla continues to support global clinical research and provides MDMA for treatments in Canada and Australia.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.
